ATE261721T1 - System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung - Google Patents

System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung

Info

Publication number
ATE261721T1
ATE261721T1 AT97927181T AT97927181T ATE261721T1 AT E261721 T1 ATE261721 T1 AT E261721T1 AT 97927181 T AT97927181 T AT 97927181T AT 97927181 T AT97927181 T AT 97927181T AT E261721 T1 ATE261721 T1 AT E261721T1
Authority
AT
Austria
Prior art keywords
drug
nanoparticles
specific target
mammalian body
stabilizers
Prior art date
Application number
AT97927181T
Other languages
English (en)
Inventor
Bernhard A Sabel
Ulrike Schroeder
Original Assignee
Nanopharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanopharm Ag filed Critical Nanopharm Ag
Application granted granted Critical
Publication of ATE261721T1 publication Critical patent/ATE261721T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
AT97927181T 1997-06-13 1997-06-13 System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung ATE261721T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1997/003099 WO1998056361A1 (en) 1997-06-13 1997-06-13 Drug targeting system, method of its preparation and its use

Publications (1)

Publication Number Publication Date
ATE261721T1 true ATE261721T1 (de) 2004-04-15

Family

ID=8166655

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97927181T ATE261721T1 (de) 1997-06-13 1997-06-13 System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung

Country Status (9)

Country Link
US (1) US7025991B2 (de)
EP (1) EP0986373B1 (de)
JP (1) JP3778575B2 (de)
AT (1) ATE261721T1 (de)
AU (1) AU3176097A (de)
CA (1) CA2295177C (de)
DE (1) DE69728179T2 (de)
ES (1) ES2218685T3 (de)
WO (1) WO1998056361A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE261721T1 (de) 1997-06-13 2004-04-15 Nanopharm Ag System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
US7651875B2 (en) * 1998-06-08 2010-01-26 Borealis Technical Limited Catalysts
WO2000074658A1 (en) * 1999-06-02 2000-12-14 Medinova Medical Consulting Gmbh Use of drug-loaded nanoparticles for the treatment of cancers
AU5218500A (en) * 1999-06-22 2001-01-09 Aventis Research & Technologies Gmbh & Co. Kg Stable, radioactively marked nanoparticles, method for the production and utilization thereof
WO2001091808A2 (en) * 2000-06-01 2001-12-06 The Board Of Regents For Oklahoma State University Bioconjugates of nanoparticles as radiopharmaceuticals
DE10121982B4 (de) * 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7381426B2 (en) * 2002-01-24 2008-06-03 Southwest Research Institute Targeted delivery of bioactive factors to the systemic skeleton
US20050222061A1 (en) * 2002-04-18 2005-10-06 Schulte Ralf W Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004017945A1 (en) * 2002-07-29 2004-03-04 Nanodel Technologies Gmbh Nanoparticles for dna administration to a target organ
US7618948B2 (en) * 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US20050053668A1 (en) * 2003-08-21 2005-03-10 Southwest Research Institute Skeletally targeted nanoparticles
JP2007520555A (ja) * 2004-02-05 2007-07-26 バクスター・インターナショナル・インコーポレイテッド 自己安定化剤の使用により調製された分散剤
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
JP2008513363A (ja) * 2004-09-14 2008-05-01 ナノデル テクノロジーズ ゲーエムベーハー ナノ粒子を含む送達媒体
EP1661559A1 (de) * 2004-11-25 2006-05-31 NanoDel Technologies GmbH Verabreichungssystem hergestellt durch ein Miniemulsionsverfahren
WO2006056362A2 (en) * 2004-11-25 2006-06-01 Nanodel Technologies Gmbh Delivery vehicle manufactured by the miniemulsion method
US20090280064A1 (en) * 2005-06-24 2009-11-12 Rao Papineni Transdermal delivery of optical, spect, multimodal, drug or biological cargo laden nanoparticle(s) in small animals or humans
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
WO2007072982A1 (en) * 2005-12-20 2007-06-28 Fujifilm Corporation Protein nanoparticles and the use of the same
EP1815851A1 (de) * 2006-02-03 2007-08-08 NanoDel Technologies GmbH Nanopartikel zur Arzneistoffverabreichung
DE102006013531A1 (de) 2006-03-24 2007-09-27 Lts Lohmann Therapie-Systeme Ag Polylactid-Nanopartikel
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
ATE510538T1 (de) 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
JP5201763B2 (ja) * 2007-02-28 2013-06-05 昇一 城武 異なる平均粒径サイズの粒子からなる混合微粒子カプセルの製造方法
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
MX2010012137A (es) * 2008-05-06 2010-12-17 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos.
JP5832293B2 (ja) 2008-12-04 2015-12-16 オプコ ファーマシューティカルズ、エルエルシー 血管新生促進vegfイソ型を選択的に抑制する組成物および方法
US10105317B2 (en) * 2009-07-07 2018-10-23 Anpac Bio-Medical Science Co., Ltd. Method of drug delivery
US8828246B2 (en) * 2010-02-18 2014-09-09 Anpac Bio-Medical Science Co., Ltd. Method of fabricating micro-devices
US10463633B2 (en) * 2010-04-23 2019-11-05 Kempharm, Inc. Therapeutic formulation for reduced drug side effects
US10555911B2 (en) 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
EP3004183B1 (de) 2013-05-28 2017-07-05 Sintef TTO AS Verfahren für die bereitstellung von tarnkappen-nanopartikels
EP3541358A1 (de) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermale verabreichung von grossen wirkstoffen
KR20190097729A (ko) * 2018-02-13 2019-08-21 서강대학교산학협력단 안질환 치료용 약물 전달 임플란트 및 이의 제조방법
JP7461932B2 (ja) 2018-08-23 2024-04-04 シンテフ ティーティーオー エイエス ナノ粒子
WO2020056191A1 (en) 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
US12357581B2 (en) 2019-04-10 2025-07-15 Sinteff Tto As Nanoparticles comprising copolymeric or homopolymeric compounds which comprise cyanoacrylate subunits

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634397B2 (fr) 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
FR2612400A1 (fr) * 1987-03-16 1988-09-23 Centre Nat Rech Scient Microcapsules contenant un marqueur radioactif et/ou paramagnetique sous forme de chelate, et leur utilisation dans le domaine de l'imagerie medicale
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
AU5714194A (en) * 1993-01-11 1994-08-15 Abacol Limited Small diameter nanocapsules, process for their preparation and applications thereof
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
JP2930421B2 (ja) 1994-02-28 1999-08-03 メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤組成物、その製造方法及びその使用方法
US5837221A (en) * 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
ATE261721T1 (de) 1997-06-13 2004-04-15 Nanopharm Ag System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
DE19745950A1 (de) 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
WO2000074658A1 (en) 1999-06-02 2000-12-14 Medinova Medical Consulting Gmbh Use of drug-loaded nanoparticles for the treatment of cancers

Also Published As

Publication number Publication date
US7025991B2 (en) 2006-04-11
CA2295177C (en) 2007-01-09
US20020034474A1 (en) 2002-03-21
AU3176097A (en) 1998-12-30
ES2218685T3 (es) 2004-11-16
EP0986373B1 (de) 2004-03-17
JP2001502721A (ja) 2001-02-27
DE69728179D1 (de) 2004-04-22
DE69728179T2 (de) 2004-11-25
WO1998056361A1 (en) 1998-12-17
JP3778575B2 (ja) 2006-05-24
CA2295177A1 (en) 1998-12-17
EP0986373A1 (de) 2000-03-22

Similar Documents

Publication Publication Date Title
DE69728179D1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
ATE228832T1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
DE3853853T2 (de) Verabreichungsformen für Pharmaka.
WO2001037896A3 (en) Methods and compositions for administration of therapeutic reagents
JPS63203629A (ja) コルチコステロイド類と組み合わせたジラーゼ阻害剤の局所的適用可能な配合物
EP1808438A3 (de) Reinigung und Stabilisierung von Peptiden und Proteinen in pharmazeutischen Wirkstoffen
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
EP1570823A3 (de) Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
CA2183871A1 (en) Platelet growth accelerator
JPH0623112B2 (ja) コラ−ゲン性医薬組成物
NO934425L (no) Preparater for nanopartikkelformige röntgenkontrastmidler
JP2002532432A5 (de)
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
DE69614419T2 (de) Transdermale Formulierung eines Mittels muscarinischer Wirkung
DE50206912D1 (de) Verfahren zur kontinuierlichen herstellung und beschichtung von selbstklebemassen auf basis von sbc mit mindestens einem pharmazeutischen wirkstoff
ATE546136T1 (de) Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemitteln
KR20080031394A (ko) Tgf-베타 수퍼패밀리 구성원을 포함하는 약학 조성물
KR20000076326A (ko) 고체 입자 형성용 조성물
US4876086A (en) Injectable compositions of amoxycillin trihydrate
JP2002535293A (ja) 無針の経皮的粉末薬物送達を増強する方法
RU2141819C1 (ru) Мазь с интерфероном человеческим лейкоцитарным "интерон"
WO2002045867A1 (de) Verfahren zur herstellung eines partiellen oder vollständigen wirkstoffüberzuges auf und in implantaten und onplantaten
US20060165611A1 (en) Composition for Treating and Preventing Periodontal Disease and Method of Use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties